Nivolumab improves the proportion of lung cancer patients alive after more than a year

(ECCO-the European CanCer Organisation) Updated results from the CheckMate 057 phase III clinical trial show that nivolumab continues to show an overall survival benefit compared to docetaxel in patients with non-squamous non-small cell lung cancer.